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OVERVIEW
Connecticut’s continuing role in advancing
stem cell research
Jessica McDonald
Editor-in-chief, Yale Journal of Biology and Medicine, New Haven, Connecticut
New Haven was the proud host of
StemCONN 09, Connecticut’s Interna-
tional Stem Cell Research Symposium, in
March. Buzzing with academic researchers,
students, and biotech entrepreneurs, it was
the second such conference in the state
since Connecticut became the third state to
devote funds to stem cell research.
The symposium highlighted work that
otherwise would have required private
money. Under President George W. Bush,
policy limited federal funding to research
on human embryonic stem cell (hESC†)
lines derived prior to 9 p.m. on August 9,
2001. That federal ban on funding the cre-
ation of and work with new hESC lines,
given that the available lines were far fewer
than initially expected and lacking in ge-
netic diversity, first galvanized New Jersey
and California to open up their own coffers
to researchers in 2004.
In June 2005, Connecticut Gov. M.
Jodi Rell followed suit, signing legislation
allocating $100 million over 10 years for
stem cell research. Warren Wollschlager,
chief of the Office of Research and Devel-
opment in the Connecticut Department of
Public Health, recalled that despite the ex-
citement, it wasn’t a great day for the de-
partment. The legislation mandated a stem
cell peer review panel — but no money was
provided for administrative support. Nev-
ertheless, after poring through 70 applica-
tions, the state was ready to distribute its
first awards by November 2006. Twenty-
one grants from three institutions — the
University of Connecticut, Wesleyan Uni-
versity, and Yale University — received
funding, totaling just under $20 million.At
the time, it was the largest award of public
funding in any state.
The public support for hESC research
in Connecticut encouraged private sources
to contribute as well. According to Diane
Krause, M.D., Ph.D., because the state pro-
vided $10 million, Yale was willing to
throw in an additional $80 million to create
its stem cell center.At StemCONN, Krause
was adamant that “Yale would not have a
stem cell center without the Initiative” and
went on to highlight Matthew Rodeheffer’s
work on brown fat; Michael Snyder’s ex-
ploration of differential gene expression in
neuronal differentiation; and Gene Red-
mond’s study of stem cells to treat Parkin-
son’s disease in primates, among others.
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National Institutes of Health.Yale has 19 researchers with ongoing
grants from the state.The university created
hESC culture, genomics and bioinformatics,
cell imaging, and FACS cores — all of
which Krause says are “highly functional
and very busy” — and was able to hire nine
new investigators, including the director of
the Yale Stem Cell Center, Haifan Lin. Re-
cruited from Duke University, Lin focuses
on piwi/argonaute genes, a particularly in-
teresting group because they are the only
known gene families required for stem cell
self-renewal in both animal and plant king-
doms.
Marc Lalande, Ph.D., of the University
of Connecticut Health Center, told a similar
tale of infrastructure development and re-
cruitment. In 2006, the state awarded a $2.5
million grant to establish a joint UConn-
Wesleyan University core laboratory. Ren-
He Xu left the WiCell Research Institute at
the University of Wisconsin to direct the
core, which, as of February, had trained
more than 100 scientists and by summer of
2010 will be relocated to a new $52 mil-
lion, 117,000-square-foot research building
on the Farmington campus. In 2008, the Xu
lab announced the creation of two hESC
lines, aptly named CT1 and CT2, which are
available to outside researchers upon re-
quest.
In addition to supporting stem cores and
establishing cell lines, state funding also has
enabled certain stem cell research projects
with particular clinical applications. Laura
Grabel, Ph.D., of Wesleyan University, ex-
plained that she began with a single grad stu-
dent; now about 10 people are working on
her research. Grabel’s work, in collaboration
with Janice Naegele of Wesleyan and
GlosterAaron of the UConn Health Center,
is to devise stem cell-based therapies for
temporal lobe epilepsy (TLE). In TLE, re-
curring seizures often result in selective
death of neurons in the hippocampus. If re-
searchers can differentiate embryonic stem
cells into neural stem cells, and ultimately
create new neurons — including inhibitory
neurons to limit brain excitability — they
can begin to “fill in gaps” for the patients
and ameliorate the disease. So far, Grabel’s
data is promising; she can point to striking
images of bright red neural rosettes, well on
their way to becoming neurons, after just
two weeks in culture.
Indeed, the allure of stem cell research,
particularly to the public at large, is the
promise that multipotent cells will deliver in
the clinic. Milton Wallack, co-chairman of
the Connecticut Stem Cell Coalition, says
that the goal ultimately is to “unlock the se-
crets of stem cells and move this research
closer to therapies.” According to Wallack,
Connecticut aims to continue its support of
basic research, as well as targeting cancer,
and begin to make regenerative medicine
breakthroughs in 10 to 15 years.
As of May 2009, five other states have
followed Connecticut in their public support
of stem cell research: New York, Maryland,
Iowa, Massachusetts, and Illinois. Most dra-
matically, on March 9, President Obama
signed an executive order rescinding Presi-
dent Bush’s 2001 limitations on hESC re-
search [1].At StemCONN, which took place
justtwoweeksafterObama’sannouncement,
researchers were buoyed by the repeal, and
Wollschlagerwasoptimisticit“willbringthe
change so many scientists have fought for.”
Although the Dickey-Wicker amend-
ment is still in effect, it restricts funding only
from hES line creation, so work with the
new CTlines, for example, will likely be el-
igible for federal funds.The executive order
itself did not detail which cell lines could or
could not be used or in what ways, but in-
stead deferred to the National Institutes of
Health (NIH) to develop ethical guidelines
within 120 days. The draft guidelines were
made available in April to allow the public
to comment on them; the final guidelines
were established on July 7.
One of many researchers who gave
input to the NIH, Krause was disappointed
that the “resulting guidelines still leave in
place significant limitations to federal fund-
ing and have, temporarily, left the research
community ‘on hold’regarding federal fund-
ing while additional details are being
worked out.” One of the primary drawbacks,
says Krause, is that funding is provided only
to hESC lines created using unwanted em-
98 McDonald: Connecticut’s role in stem cell researchbryos following fertility treatment. This ef-
fectively excludes methods such as somatic
cell nuclear transfer, which holds “particular
promise for studying the genetic basis of
certain human diseases.” Also troublesome
is that because of the new guidelines’ more
specific informed consent requirements, cer-
tain hESC cell lines previously funded under
Bush may in fact no longer be eligible. As
time passes, however, the collective changes
to federal law will result in more, not less,
eligible cell lines.
With new opportunities for federal
funds, coupled with the economic downturn
that has wreaked havoc on many state budg-
ets, it remains to be seen whether states with
ongoing hESC research programs will con-
tinue to support them. But given that there
is “still very limited” federal funding, and
Connecticut law is clear about which lines
can be studied, Krause is convinced state
money is as important as ever.Wollschlager
said that the 2007 conference celebrated the
fact that Connecticut was “in the game;” the
2009 conference was able to celebrate the
“work being done.” Researchers certainly
hope the latter will be said of the next con-
ference. For now, it appears they will be able
to, since the recipients of the most recent
grants, totaling $9.8 million, were an-
nounced inApril.
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